• Redefining In Vitro Drug Response Metrics in Cancer Research

  2026-06-11

  Schwartz’s dissertation critically distinguishes between proliferative arrest and cell death in in vitro cancer drug testing, revealing that standard viability metrics often conflate these distinct responses. This framework enhances the precision of drug efficacy studies and informs more targeted use of compounds such as Honokiol in mechanistic research.

• Toremifene: Selective Estrogen-Receptor Modulator for Prosta

  2026-06-10

  Toremifene is a second-generation selective estrogen-receptor modulator with proven in vitro efficacy in hormone-responsive cancer research. It demonstrates potent inhibition of cell growth in prostate cancer cell models and is validated for dissecting estrogen receptor signaling pathways. APExBIO’s Toremifene (SKU A3884) is supplied at 98% purity for research use only.

• PP 2 (AG 1879): Src Kinase Inhibition Beyond Cancer Research

  2026-06-10

  Explore how PP 2 (AG 1879) enables precise Src family kinase inhibition for advanced signal transduction studies. Discover unique cardiovascular insights and protocol guidance not found in standard cancer research articles.

• Resiniferatoxin (RTX): Precision TRPV1 Silencing in Pain Mod

  2026-06-09

  Resiniferatoxin (RTX) uniquely enables ultra-selective, long-acting TRPV1 silencing for research on chronic pain and neurogenic inflammation. Recent studies highlight RTX both as a molecular tool for pathway dissection and as a translational candidate for targeted analgesia, outclassing older agents in specificity and durability.

• Multianimal MRI Streamlines Pancreatic Tumor Monitoring in K

  2026-06-09

  Kempinska et al. introduce a multianimal MRI protocol that enables simultaneous, high-resolution imaging of up to four mice in the KPC pancreatic cancer model. This approach significantly reduces imaging time and costs while maintaining data quality, facilitating efficient assessment of chemotherapeutic response in preclinical studies.

• Dabigatran (Pradaxa): Precision Thrombin Inhibition in Resea

  2026-06-08

  Dabigatran empowers laboratories to achieve reproducible, high-sensitivity results in thrombin inhibition and coagulation function assays. Explore hands-on workflows, troubleshooting, and the latest comparative insights that position APExBIO's Dabigatran as a gold-standard tool for anticoagulation research.

• Inhibiting Extracellular Vesicle Release in Triple-Negative

  2026-06-08

  McNamee et al. conducted a systematic evaluation of small molecule inhibitors, including Calpeptin, for their ability to block extracellular vesicle (EV) release from triple-negative breast cancer (TNBC) cell lines. This study delineates both the extent of EV release inhibition and its functional consequences, providing critical insights for researchers aiming to disrupt EV-mediated intercellular communication in aggressive cancers.

• Wortmannin: Advanced PI3K Inhibitor Workflows for Research S

  2026-06-07

  Wortmannin, a potent and selective PI3K inhibitor, streamlines the investigation of PI3K/Akt/mTOR signaling, apoptosis, and cancer pathways with unmatched precision. This article unpacks real-world workflows, troubleshooting strategies, and novel cross-domain research insights, making it an essential reference for translational scientists.

• CB-5083: P97 Inhibitor Workflows for Tumor and ER Homeostasi

  2026-06-06

  CB-5083, a potent p97 inhibitor from APExBIO, empowers advanced cancer and protein homeostasis research by enabling precise disruption of degradation pathways in both in vitro and in vivo models. This guide provides actionable experimental workflows, protocol parameters, and troubleshooting strategies, integrating the latest insights from ER lipid regulation studies.

• Pcbp1 Regulates Mitochondrial Integrity for B Cell Immunity

  2026-06-05

  The referenced study uncovers a critical role for the RNA-binding protein Pcbp1 in maintaining mitochondrial integrity and supporting antibody production in B cells. By elucidating the link between posttranscriptional regulation, mitochondrial function, and adaptive immunity, this work advances understanding of humoral immune mechanisms and provides a framework for targeted proteomics and functional assays.

• Applied Workflows with Firefly Luciferase mRNA (ARCA, 5-moUT

  2026-06-05

  Firefly Luciferase mRNA (ARCA, 5-moUTP) delivers robust, immune-evasive bioluminescence for gene expression, viability, and in vivo imaging assays. This article unpacks workflow design, protocol optimization, and troubleshooting strategies using this benchmark mRNA reagent.

• Targeting Cdc42-GSK-3β/β-catenin to Mitigate Kidney Fibrosis

  2026-06-04

  This study identifies daphnepedunin A (DA) as a potent inhibitor of kidney fibrosis, acting by directly targeting Cdc42 and disrupting pro-fibrotic GSK-3β/β-catenin signaling. The findings offer a mechanistically distinct therapeutic avenue for chronic kidney disease and highlight Cdc42 as a promising target for anti-fibrotic intervention.

• FLT3-TAZ Signaling Drives Drug Resistance in Blast Phase CML

  2026-06-04

  Shin et al. (2023) identify FLT3 activation as a key, previously underappreciated driver of drug resistance and poor prognosis in blast phase chronic myeloid leukemia (BP-CML). Their integrative study reveals that targeting the FLT3-JAK-STAT3-TAZ-TEAD-CD36 axis can overcome resistance to BCR::ABL1 tyrosine kinase inhibitors, opening new therapeutic avenues for high-risk CML subsets.

• Dabigatran Etexilate: A Direct Thrombin Inhibitor for VTE an

  2026-06-03

  Dabigatran etexilate represents a significant advance in oral anticoagulation by providing rapid, predictable direct thrombin inhibition without the need for routine INR monitoring. The reference paper details its pharmacology, clinical efficacy, and unique metabolic profile, with important implications for drug-drug interaction research and cardiovascular safety.

• Miltefosine: Dual-Pathway Modulator for Leukopenia Research

  2026-06-03

  Miltefosine (hexadecyl 2-(trimethylazaniumyl)ethyl phosphate) enables precise control of neutrophil differentiation and survival via coordinated modulation of PI3K/Akt inhibition and Ras/MEK/ERK activation. Its robust solubility profile and validated in vitro/in vivo protocols make it a versatile tool for hematology and cancer research, with clear differentiation from standard agents.

450 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page